⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 4, 2024Journal of Medical EconomicsOpen Access

Evaluating cost-effectiveness of PFO management strategies: closure with cardioform vs. amplatzer, and treatment with medical therapy alone, for secondary stroke prevention

John Volpi Lambertus F. Wolters Timon Louwsma Mitesh Nakum Ryan J. Imhoff Erik J. Landaas

View Full Paper

Ask AI

Bookmark

Share

Abstract

The aim of this study was to evaluate the cost-effectiveness of patent foramen ovale (PFO) closure using CARDIOFORM Septal Occluders versus AMPLATZER Septal Occluders, as well as compared to Medical Therapy Alone, from a payor perspective in the United States.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Volpi et al. (2024) studied this question.

synapsesocial.com/papers/68e55c8ae2b3180350efa37f https://doi.org/10.1080/13696998.2024.2412948

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cost-effectiveness and budget impact of PFO closure: Cardioform vs Amplatzer and medical therapy for secondary stroke prevention in AustraliaCost-Effectiveness Analysis · 2026 · 1 citations
2Cost-Effectiveness and Budget Impact of Cardioform versus Amplatzer and Medical Therapy Alone for Patent Foramen Ovale Closure: A UK Payer Perspectiveother · 2026
3Cost-effectiveness analysis of Cardioform vs. Amplatzer: concerns regarding methodological transparency and interpretation of clinical resultseditorial · 2026
4Percutaneous patent foramen ovale closure for secondary stroke preventionmeta-analysis · 2018 · 35 citations
5Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysismeta-analysis · 2014 · 131 citations

More related papers

Patent foramen ovale closure versus medical therapy for cryptogenic stroke: An updated systematic review and meta-analysis2019
Percutaneous Closure Versus Medical Treatment in Stroke Patients With Patent Foramen Ovale2018
Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials2018

More from Journal of Medical Economics

Cost‑effectiveness analysis of the mRNA‑1345 RSV vaccine for older adults in ItalyMon,
Morbidity burden and healthcare costs in idiopathic multicentric Castleman disease (BURDEN-iMCD): a retrospective population-level matched cohort analysisSun,